USPTO serial 90867023
COSMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 8, 2024
- Examiner
- BARREDA, AMBER KYLEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with COSMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seattle, WA
Seattle, WA
BILLERICA, MA
BILLERICA, MA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alyssa M. Worsham
Alyssa M. Worsham WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents, namely, assays for scientific research and non-medical and non-veterinary diagnostic use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for scientific and research use in the fields of cancer, neurology and infectious disease; reagents for scientific research and non-medical and non-veterinary diagnostic use relating to molecular identification and digital quantification; reagents for scientific research and non-medical and non-veterinary diagnostic use containing antibodies and nucleic acids; reagent kits comprising primarily reagents for scientific research and non-medical and non-veterinary diagnostic use in the fields of cancer, neurology and infectious disease; reagents for immunohistochemistry detection and in situhybridization detection for scientific research and non-medical and non-veterinary diagnostic use; chemical test kits for scientific research and non-medical and non-veterinary diagnostic use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation, namely, instructional manuals, therefor; chemical test kits comprising reagents for scientific research and non-medical and non-veterinary diagnostic use relating to molecular identification and digital quantification; reagents for in vitro use in clinical chemistry and molecular biology; reagents for clinical and medical laboratory use, namely, reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling, nucleic acid sequencing, and clinical, oncology, neurology, and infectious disease diagnostics; multiparameter quantitative detection and analysis products and technology for research and diagnostics for a variety of uses in the health care and other life science sectors, namely, reagents for scientific or medical research use, diagnostic preparations and reagents for scientific and research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; chemical test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers | ACTIVE | Nov 9, 2021 |
| 005 | Diagnostic reagents, namely, assays for medical and veterinary use in the fields of pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical and veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical and veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical and veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily of reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical and veterinary diagnostic kits comprising primarily of medical and veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical and veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical and veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products, namely, reagents and assays for medical diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids and tissue; diagnostic reagent kits consisting primarily of medical and veterinary diagnostic reagents and assays for testing of body fluids and tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical and veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situhybridization detection | ACTIVE | Nov 9, 2021 |
| 009 | Automated apparatus in the nature of automated laboratory equipment, namely, computer and networking hardware, and computer systems comprised of computer hardware and downloadable computer software for detection and analysis of biomolecules for scientific use; automated apparatus in the nature of automated laboratory equipment, namely, computer and networking hardware and computer systems comprised of computer hardware and downloadable computer software for scientific research, namely, for detecting, collecting and processing optical signals and images, into data for use in the analysis of biomolecules in connection with scientific and medical research; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, fluidic stations in the nature of automatic fluid-composition control machines and instruments, and computer systems comprised of computer hardware and downloadable computer software for staining and visualization of tissue and cell based samples for diagnostic and scientific use; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots and computer systems comprised of computer hardware and downloadable computer software for digitizing images of biological tissue for use in connection with pathology; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, and computer systems comprised of computer hardware and downloadable computer software for capturing digital images of microscope slides of biological tissue, storage of digitized microscope slide images in a data storage area, and display of digitized microscope slide images; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, fluidic stations in the nature of automatic fluid-composition control machines and instruments, and computer systems comprised of computer hardware and downloadable computer software for detection and analysis of, pathology, gene expression, RNA transcription, RNA translation and nucleic acid sequencing; computer hardware and downloadable computer software to enable pathologists to diagnose disease; computer hardware and downloadable computer software for the electronic scanning of clinical pathology slides; computer hardware and downloadable computer software for pathologists to render and report diagnoses and results of scientific research; computer hardware and downloadable computer software for scientific and research uses in the fields of pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription and microRNA expression profiling and nucleic acid sequencing; computer hardware and downloadable computer software for digitizing, processing and storing images of biological tissues and cells; computer hardware and downloadable computer software for analyzing the results of tissues and cell based samples obtained through operation of tissue and cell sample staining and visualization apparatus; computer hardware and downloadable computer software for identifying and diagnosing cancer and other diseases and processing digital images; computer hardware and downloadable computer software for viewing, analyzing, managing, reporting, and archiving digital images; laboratory equipment for sample preparation, mixing, hybridization, incubation, washing, location and imaging, namely, robotic equipment, fluid mixers, pumps, valves, and containers, reagent holders, sample containers and microfluidic devices, optical devices, scanning microscopes, fluorescent microscopes, digital micromirror devices, electromagnetic sensors and replacement parts therefor in the fields of scientific research; downloadable computer application software for computer systems, namely, software and data files, namely, csv, TIF, png, JPEG, and fth files to acquire, analyze, manage and report biological information | ACTIVE | Nov 9, 2021 |
| 010 | Clinical and medical diagnostic instruments, namely, spatial molecular imagers, namely, devices for the detection, visualization and analysis of biological molecules at cellular and subcellular resolution; clinical and medical diagnostic instruments, namely, histopathology instruments and nucleic acid sequencers; clinical and medical diagnostic instruments for analysis of tissue and cell based samples, all for medical purposes; clinical and medical diagnostic instruments for performing immunohistochemistry and in situ-hybridization staining reactions, histological and pathological staining and image processing and analysis; histopathology instruments for clinical purposes; clinical and medical diagnostic instruments for immunohistochemistry and in situ-hybridization analyses; clinical and medical diagnostic instruments for the electronic scanning of clinical pathology slides, processing and storing images of biological tissues and cells and digitizing, processing and storing images of biological tissues and cells | ACTIVE | Nov 9, 2021 |
| 042 | research and product development services for others in the field of biotechnology; medical and scientific research services for others in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research services for others in the field of infectious disease; medical and scientific research services for others in the field of neurology; medical and scientific research services for others, namely, research and design in the field of testing, analyzing and examining biological samples, medical samples, and cell samples; providing laboratory research services for others in the field of gene expression and genetic data mining; research and development services for others for acquiring, analyzing, and managing biological and genetic information in the fields of forensics, medicine, genetics, and environment; Scientific research, design, and development services, for others, of single-cell imaging products for acquiring, analyzing, and managing diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation processes, data acquisition, analysis, management and reporting of biological information in the fields of healthcare, pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing | ACTIVE | Nov 9, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NanoString Technologies, Inc.
- Other trademarks owned by NanoString Technologies, Inc.
- Other trademarks owned by BRUKER SPATIAL BIOLOGY, INC.
- Other trademarks owned by BRUKER SPATIAL BIOLOGY, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named COSMX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 8, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 8, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 4, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Sep 4, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Sep 4, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2024 | ALIE | ASSIGNED TO LIE | — |
| Jul 4, 2024 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 20, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 5, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 6, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 5, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 14, 2023 | IUAF | USE AMENDMENT FILED | — |
| Dec 14, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 25, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 30, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 30, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 10, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 25, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 13, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 13, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 13, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 18, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 17, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 13, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 13, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 13, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 24, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 24, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 28, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 28, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 28, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 12, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 12, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 4, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 30, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 9, 2021 | NWAP | NEW APPLICATION ENTERED | — |